wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q26775947-3E7DDD3D-5A58-4577-9FE6-A5E8D25D89F2
Q26775947-3E7DDD3D-5A58-4577-9FE6-A5E8D25D89F2
BestRank
Statement
http://www.wikidata.org/entity/statement/Q26775947-3E7DDD3D-5A58-4577-9FE6-A5E8D25D89F2
Anti-angiogenic alternatives to VEGF blockade
P2860
Q26775947-3E7DDD3D-5A58-4577-9FE6-A5E8D25D89F2
BestRank
Statement
http://www.wikidata.org/entity/statement/Q26775947-3E7DDD3D-5A58-4577-9FE6-A5E8D25D89F2
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
867be2b6abdf403d207a1aed72c1fecdc035fbc6
P2860
An open-label phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) with bevacizumab in patients with advanced cancer.